1114563-10-8

Usage

Uses

Used in Organic Synthesis:
5-bromo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one is used as a key intermediate in organic synthesis for the creation of various chemical compounds due to its unique structural features.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-bromo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one is utilized as a starting material for the development of pharmaceuticals, leveraging its potential pharmacological properties.
Used in Drug Development:
5-bromo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one is employed as a structural component in drug development, where its bromine atom and trifluoroethyl group can be modified to improve the compound's biological activity and therapeutic efficacy.
Used in Agrochemical Development:
5-bromo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one also finds application in agrochemical development, where its properties can be harnessed to create new pesticides or herbicides with enhanced performance.
Overall, 5-bromo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one is a versatile compound with significant applications across the fields of chemistry and pharmaceutical research, making it an important asset for the advancement of new chemical entities.

Upstream product

• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 13466-38-1 5-bromopyridin-2-ol 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 

Relevant academic research and scientific papers

SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF

Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.